2000
Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial
Mulnard R, Cotman C, Kawas C, van Dyck C, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal L, Study F. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial. JAMA 2000, 283: 1007-1015. PMID: 10697060, DOI: 10.1001/jama.283.8.1007.Peer-Reviewed Original ResearchConceptsEstrogen replacement therapyModerate Alzheimer's diseaseSecondary outcome measuresReplacement therapyAlzheimer's diseaseOutcome measuresClinical trialsPlacebo-controlled clinical trialMini-Mental State Examination scoreAlzheimer's Disease Cooperative StudyPrevention of ADClinical Dementia Rating ScaleClinical Global ImpressionPrimary outcome measureTreatment of mildSmall clinical trialsRole of estrogenState Examination scoreDementia Rating ScaleCGIC scoresEstrogen groupPlacebo groupControlled TrialsFunctional outcomeGlobal Impression
1994
SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine
van Dyck C, Rosen M, Thomas H, McMahon T, Wallace E, O'Connor P, Sullivan M, Krystal J, Hoffer P, Woods S, Kosten T. SPECT regional cerebral blood flow alterations in naltrexone-precipitated withdrawal from buprenorphine. Psychiatry Research 1994, 55: 181-191. PMID: 7701033, DOI: 10.1016/0925-4927(94)90013-2.Peer-Reviewed Original ResearchConceptsRegional cerebral blood flowRegional cerebral blood flow alterationsCerebral blood flow alterationsHexamethyl propylene amine oximeOpiate-induced analgesiaBlood flow alterationsSeverity of withdrawalCerebral blood flowOpiate-dependent patientsAnterior cingulate regionsAnterior cingulate cortexSingle photon emissionPlacebo administrationAmine oximeOpiate withdrawalRCBF ratiosWithdrawal severityBlood flowCingulate cortexCingulate regionsSignificant negative correlationBuprenorphineNaltrexonePlaceboPatients